RxDoctor Payments Data

Christopher Bailey, MD

Internal Medicine · Rainbow City, ALNPI 1750609350

Payments from drug & device makers

$1,238in general payments, 2019–2025

Across 50 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$510
  • Johnson & Johnson$206
  • GSK$115
  • Pfizer$78
  • AbbVie$77
  • Novo Nordisk$75
  • plus $178 from 8 others

What the payments were for

  • Food & beverage$1,238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,238 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$90,558
Medicare patients
332
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$68,542
EliquisApixaban71$61,558
MounjaroTirzepatide43$50,937
JardianceEmpagliflozin36$40,040
FarxigaDapagliflozin Propanediol45$26,644
JanuviaSitagliptin Phosphate17$22,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,238
Xigduo XrDapaglifloz Propaned/Metformin22$16,414
Breo ElliptaFluticasone/Vilanterol19$12,844
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,218
EntrestoSacubitril/Valsartan13$8,473
Spiriva RespimatTiotropium Bromide16$7,948
Testosterone20$4,890
DuleraMometasone/Formoterol12$3,840
Atorvastatin Calcium267$3,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$75$68,54268 claims
PfizerEliquis$78$61,55871 claims
AstraZenecaFarxiga, Breztri Aerosphere$510$38,86265 claims
GSKTrelegy Ellipta, Breo Ellipta$115$34,08245 claims
AbbVieSynthroid$77$2,64543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Rainbow City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →